Swedish Orphan Biovitrum AB BIOVF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BIOVF is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $25.00
- Day Range
- $22.87–23.74
- 52-Week Range
- $18.35–27.79
- Bid/Ask
- $24.21 / $25.22
- Market Cap
- $7.77 Bil
- Volume/Avg
- 3,000 / 490
Key Statistics
- Price/Earnings (Normalized)
- 28.52
- Price/Sales
- 3.58
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement programs in 2006. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016. Sobi has since been building its immunology pipeline (rare disease drug Gamifant, U.S. rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and hematology pipeline outside of hemophilia (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 1,772
- Website
- https://www.sobi.com
Competitors
Valuation
|
Metric
|
BIOVF
|
CSL
|
RHHBY
|
|---|---|---|---|
Price/Earnings (Normalized) | 28.52 | 28.43 | 11.10 |
Price/Book Value | 2.29 | 5.28 | 5.52 |
Price/Sales | 3.58 | 6.32 | 2.89 |
Price/Cash Flow | 13.99 | 32.99 | 10.64 |
Price/Earnings
BIOVF
CSL
RHHBY
Financial Strength
|
Metric
|
BIOVF
|
CSL
|
RHHBY
|
|---|---|---|---|
Quick Ratio | 0.42 | 0.95 | 0.99 |
Current Ratio | 0.66 | 2.15 | 1.35 |
Interest Coverage | 3.63 | 7.21 | 14.93 |
Quick Ratio
BIOVF
CSL
RHHBY
Profitability
|
Metric
|
BIOVF
|
CSL
|
RHHBY
|
|---|---|---|---|
Return on Assets (Normalized) | 4.16% | 8.11% | 17.03% |
Return on Equity (Normalized) | 9.13% | 18.17% | 53.42% |
Return on Invested Capital (Normalized) | 7.62% | 10.94% | 26.30% |
Return on Assets
BIOVF
CSL
RHHBY
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ZTS
| Zoetis Inc Class A | Sxpjkftxh | Ntrp | $70.0 Bil | |
MKKGY
| Merck KGaA ADR | Zsjlsthzvw | Tfvzxct | $68.4 Bil | |
HLN
| Haleon PLC ADR | Snrxrtpnx | Kbqn | $37.0 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Rpbmfmn | Bwjk | $14.5 Bil | |
VTRS
| Viatris Inc | Hqcbnqbd | Rksp | $13.4 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Djfkvqzp | Jsbn | $12.0 Bil | |
CTLT
| Catalent Inc | Bqwvtsgm | Zpbwj | $10.1 Bil | |
PRGO
| Perrigo Co PLC | Cntbnmbsq | Sgd | $4.1 Bil | |
CURLF
| Curaleaf Holdings Inc | Dzttznjt | Lvhvm | $3.6 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Vkvdftvc | Xzfdvz | $3.5 Bil |